AMGEN Message Board - Msg: 423154

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMGEN

AMGN 296.30

-0.7%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: YOAV KEDAR who wrote (39)	11/6/1996 5:09:00 PM
From: gary althoff	of 42

I have been wondering why AMGN has been trending down the last few days. Now I know. Use little guys are always the last to know! Does anyone have any idea if the patent is valid? ================================================================= WASHINGTON -- Genentech Inc. (GNE) filed suit against Amgen Inc. (AMGN) accusing it of infringing on certain of its patented cloned-gene expression methods by manufacturing and selling Neupogen, one of Amgen's two major products. The suit, filed on Oct. 16 in federal court in Northern California, alleges that Amgen is infringing on 3 distinct Genentech patents and seeks an unspecified amount of compensatory and treble damages as well as an injunction against further infringement. Amgen's sales of Neupogen, a white-blood-cell booster used in chemotherapy, rose 12% last quarter and are cited as a main reason for the continued strength of the Thousand Oaks, Calif., biotechnology company's stock. Genentech, based in South San Francisco and also a biotech company, is developing rival platelet drugs. Company officials were not immediately available to comment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next